Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26405146 | 0.88 | L3MBTL1 (0.48) | CXCR4ACHEBACE1HRH3 | |
| SCHEMBL23696174 | 0.83 | BCHE (0.49) | CXCR4ACHEBACE1 | |
| SCHEMBL24607258 | 0.82 | MAOA (0.46) | CXCR4ACHEBACE1HRH3 | |
| SCHEMBL25654352 | 0.81 | BCHE (0.45) | CXCR4ACHE | |
| SCHEMBL26409040 | 0.79 | KCNH2 (0.54) | CXCR4ACHEBACE1 | |
| SCHEMBL13428851 | 0.78 | CXCR4 (0.64) | CXCR4ACHEBACE1 | |
| SCHEMBL25927715 | 0.78 | BCHE (0.47) | CXCR4ACHE | |
| SCHEMBL23946018 | 0.77 | L3MBTL1 (0.49) | CXCR4ACHEBACE1 | |
| SCHEMBL23806785 | 0.74 | L3MBTL1 (0.51) | CXCR4ACHEBACE1HRH3 | |
| SCHEMBL8227566 | 0.73 | CXCR4 (0.54) | CXCR4ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CXCR4 2507/4885ACHE 2778/4885BACE1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.